More Tooth, More Tail in CRISPR Operations
The Most Interesting Thing about CRISPR/Cas9 Is What It Can Accomplish in the Hands of Gifted Researchers
DNA: Past to Present 2017
Celebrate National DNA Day with a Look at Some of the Double-Helix’s Scientific History
Predict Drug Toxicity without Guesswork
Consider Organs-On-Chips, Pathway Simulations, and Transgenic Mice
Cell-Line Development Poised for Growth
For Real Gains, Try Engineering Better Cell Lines
For full access to this article login to GEN Select now.
Novel ADMET Technologies Gain Traction
- Too many new drug compounds fail in late-stage clinical trials due to inefficacy and safety concerns. With often-cited costs of $800 million to bring a new drug to market, a compelling need exists for improved early-stage screening. Insufficient knowledge of potential human toxicity can turn a promising lead candidate ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.